Categories: News

Genalyte Announces Oversubscribed $50 Million Financing Round to Expand Testing Menu and Deploy Platform

SAN DIEGO, Jan. 11, 2021 /PRNewswire/ — Genalyte, a leading diagnostics and analytics company, announced today the closure of $50 million in financing.  Genalyte’s Maverick™ Diagnostic System (MDS) uses silicon chip based photonic ring resonance technology to perform multiple, simultaneous, rapid tests on a small volume of whole blood or serum in twenty minutes.

“We are energized by the very enthusiastic response from Investors for this latest round of funding,” said CEO Ashraf Hanna.  “Genalyte is uniquely positioned to improve the laboratory diagnostic and analytic space.  We’ve demonstrated the strength of our technology in our EUA authorized SARS-CoV-2 Multi-Antigen Serology Panel, which is able to measure 26 different antibodies from one drop of blood.  Independent tests by the Mayo Clinic, Scripps, and Northshore Healthcare have consistently verified the platform’s industry leading capabilities.”  

The financing round was led by Verily, an Alphabet company, and included current major investors Provenio Capital, Redmile, Khosla Ventures, HBM Partners, Samsara and others.

Andy Conrad, CEO and founder of Verily has been nominated to Genalyte’s board of directors.  “Verily and Genalyte share a common vision of empowering physicians and patients with timely insights to improve outcomes and lower the cost of care,” said Andrew Conrad.  “I look forward to working with Genalyte as they continue to innovate technology to advance rapid diagnostics and analytics.”

The company intends to utilize the funding to expand the Maverick test menu and rapidly deploy the Maverick platform in clinical and retail settings.  

About Genalyte: Genalyte is a healthcare diagnostics and analytics company that improves patient outcomes and lowers cost with real-time results for physicians and patients. Genalyte delivers rapid, actionable results to doctors through decentralized laboratory testing. For more information, please visit www.genalyte.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/genalyte-announces-oversubscribed-50-million-financing-round-to-expand-testing-menu-and-deploy-platform-301205549.html

SOURCE Genalyte Inc

Staff

Recent Posts

Glow Lifetech Announces Expansion into Manitoba Market and Portfolio Expansion in New Brunswick, Advancing National Growth Strategy

Toronto, Ontario--(Newsfile Corp. - February 3, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF)…

52 minutes ago

Massimo Group Signs Letter of Intent to Acquire 100% of AI technology company FST in Drive to Accelerate Its AI-Powered Mobility and Health Technology Strategy

GARLAND, Texas, Feb. 3, 2026 /PRNewswire/ -- Massimo Group (NASDAQ: MAMO) ("Massimo" or the "Company"),…

3 hours ago

Baysient Launches iDose® GEN7.0, Expanding Precision Dosing Platform to 16 Inflammatory Disease Indications

Next-Generation Decision Support Software Introduces Predictive Clinical Tools for Gastroenterology, Rheumatology, Dermatology, and PulmonologyFORT MYERS,…

3 hours ago

From the Founders of Fitbit: Introducing Luffu, Your Guardian for Family Health & Safety

After making personal health accessible to millions with Fitbit, James Park and Eric Friedman announce…

3 hours ago

Embla Medical hf: Interim Report Q4 and Full Year 2025

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026 Interim Report Q4 and Full…

3 hours ago

UAE Partners with Colossal Biosciences to Protect Biodiversity and Champion the Future of Life on Earth

The collaboration positions the UAE as a global leader in conservation, driving pioneering initiatives in…

3 hours ago